The Global Live Vaccines Market size was USD 16.14 billion in 2019 and is predicted to grow at a CAGR of 6.6% through the forecast period to reach over USD 26.59 billion by 2030.
The market is driven by the rising prevalence of infectious diseases such as Varicella, Polio, increasing awareness among the population, rising governmental initiatives, increasing healthcare spending capacity of individuals. Live vaccines are derived from disease-causing viruses or bacteria, which are attenuated or weakened by repeated culturing. To create an immune response individual must replicate the virus or vaccine being injected to him; this replication creates sufficient immune response in an individual body.
Increasing governmental initiative programs contributes to an increase in awareness among the nation’s population irrespective of the education and economic standard, which supports the market expansion. Indian government started its Pulse Polio program, which aims to vaccinate 100% population against Polio. The program involved the spread of awareness through different social media, plan mop-up operations, and active participation by population. Global Polio Eradication Initiative (GEPI) is funded by various public and private donors, an estimated required fund for 2013-2019 is USD 4.2 billion. Polio continues to be endemic in several countries such as Afghanistan, Nigeria and Pakistan due to lower immunity and surveillance. Viral diseases such as yellow fever is estimated to be endemic in more than 30 countries of Africa and around 11 countries of Latin America. Approximately 200,000 new incidences of yellow fever appear each year across the world and has high prevalence in densely populated developed nations such as India, China, Japan, the US, Brazil. As yellow fever vaccine is the only treatment available to treat the disease; its high prevalence across the world is contributing to the growth of market share global live vaccines industry.
Recently, wealthier states in Europe such as England and Wales lost its measles-free status due to registration of newer cases of measles and estimation of higher risk of a greater number of diagnosis later. This provides an emerging market for measles live vaccine in the region. Live vaccines are preferred over other type of vaccine as it boost an individual’s own body immune response and single dose of vaccination is sufficient to produce lifetime immunity against the respective disease.
Request a Sample@ https://qyresearchmedical.com/sample/119005
Technologically advanced live vaccines such as live recombinant vaccine uses attenuated viruses or bacteria as a vector. A gene responsible to produce protein is selected, which then target the disease-causing pathogen resulting in generation of immunity against the disease. Vaccinia virus was the first live recombinant vaccine used for the treatment of smallpox. Influenza, hepatitis B, and rabies are other examples of popular live recombinant vaccines.
The side effects such as contraindication in pregnancy, the possibility of complications in case individuals under immunosuppressant medications, associated complications in case of organ transplantation and people with already lowered immunity, and the difficulty in live vaccine storage are among major factors expected to negatively affect the market growth in the forecast period.
On the basis of type live vaccine market is segmented as bacterial and viral. The viral segment is anticipated to be the fastest-growing segment with the largest market share, followed by the bacterial segment over the forecast period.
Route of Administration Outlook:
On the basis of route of administration, injection passage for the delivery of the vaccine led the global market and generated revenue share of USD 6.27 billion by 2019. Increased prevalence of measles, typhoid, and tuberculosis, is the key factor for the surge of the injecting pathway of the live vaccines market
The live vaccine market on the basis of application is classified as measles and BCG. The measles application segment held a significant share of the global market in 2019. It accounted for 24.8% of the market share in 2019, as it is the most prevalent infectious disease around the world.
North America is the lucrative region for live vaccines market followed by Europe. North America contributes to being the high revenue generating segment due to the presence of a large number of research and development centers and biopharmaceutical companies. North America and Europe cumulatively account for a substantial revenue share in live vaccines s market, due to the high prevalence rate of infectious diseases in these regions.
Asia-Pacific market is estimated to be the fastest growing regional segment accounting market revenue of USD 3.44 billion in 2019, and CAGR of 7.2% during the forecast period; owing it to growing incidence of infectious disease and significant birth rate in emerging countries of Asia Pacific, improved regulatory framework, strong worldwide distribution network of live vaccines manufacturers, and rising public awareness related to benefits offered by live vaccines in eradication of infectious disease.
- The Global Live Vaccines Market size was USD 16.14 billion in 2019 and is predicted to grow at a CAGR of 6.6% through the forecast period to reach over USD 26.59 billion by 2030
- The measles indication segment held a significant share of the global market in 2019. It accounted for 24.8% of the market share in 2019, as it is the most prevalent infectious disease around the world
- On the basis of route of administration, injection passage for the delivery of the vaccine led the global market and generated revenue of USD 6.27 billion in 2019. Increased prevalence of measles, typhoid and tuberculosis is the key factor for the surge of the injecting pathway of the live vaccines market
- On the basis of type, viral is expected to be the fastest-growing segment with largest market share followed by the bacterial type of the live vaccines
- Due to increasing disposable income and increasing awareness towards endemic and infectious disease market growth is booming in developing countries as well as developed countries.
- The Asia-Pacific market is estimated to be the fastest-growing regional segment accounting market revenue of USD 3.68 billion in 2019, and CAGR of 7.2% during the forecast period; owing it to the growing incidence of infectious disease and significant birth rate in emerging countries of Asia Pacific, improved regulatory framework, strong worldwide distribution network of live vaccines manufacturers, and rising public awareness related to benefits offered by live vaccines in the eradication of infectious disease.
- North America is the chief revenue generator holding 37.6% of the market revenue share in 2019
Some of the prominent companies in the live vaccines market include Merck & Co., GlaxoSmithKline plc., Astellas Pharma Inc., Emergent BioSolutions, AstraZeneca plc, Serum Institute of India Pvt. Ltd., Pfizer Inc., Bharat Biotech, Sun Pharmaceutical Industries Limited, and Cipla Limited are dominating players in the market and are the companies considered for this report.
Segments covered in the Report:
This report predicts revenue growth and CAGR at a global, regional & country level, and analyses the markets by studying the drivers, constraints, opportunities, threats, challenges, investment opportunities, products, uses, trends, market shares in each of the sub-segments from 2019 to 2030. For the purpose of this study, Reports and Data have segmented the global Live Vaccines market report based on type, route of administration, application, patient use, and region:
Type Outlook (Revenue, USD Million; 2019-2030)
Route of Administration Outlook (Revenue, USD Million; 2019-2030)
- Combination of Injection and Oral
Application Outlook (Revenue, USD Million; 2019-2030)
- Yellow Fever
- Oral Polio
Patient Use Outlook (Revenue, USD Million; 2019-2030)
Regional Outlook (Revenue, USD Million; 2019-2030)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Rest of MEA
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119005/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: